AC Immune's experimental Alzheimer's-disease drug missed the mark in a midstage trial.
News & Analysis: AC Immune SA
Investors are excited about the company advancing its Alzheimer's disease vaccine, but caution is warranted.
Shares crater after the company provides investors with terrible clinical news.
The early-stage biopharma announced more details about a share offering to raise much-needed capital.